SPHK1 and adrenal cortex carcinoma: In addition, we further evaluated the effects of anti-SphK1 therapies [anti-SphK1-based small interfering RNA (siRNA) and pharmacologic inhibitior FTY720] in ACC cell lines, as a single agent or in combination with mitotane, and attempted to explore its anticarcinogenic mechanisms.